KLOW and GLOW Blends Explained: What Is in PTY-KLW and PTY-GLW
GLOW and KLOW are two of the most searched blend names in research peptides, and they are easy to mix up. The difference is one letter and one compound. This KLOW and GLOW blends explained guide reads the ingredient list for you. We name every component, give each one its research summary in a sentence or two, and explain why neither mixture has research of its own. In our catalogue the two are listed as the PTY-GLW blend and the PTY-KLW blend.
Two names, one difference
Here is the whole ingredient list, straight from our research notes.
- PTY-GLW blend (GLOW): GHK-Cu, BPC-157 and TB-500 in one vial. Three compounds.
- PTY-KLW blend (KLOW): GHK-Cu, BPC-157, TB-500 and KPV in one vial. Four compounds.
So KLOW is GLOW plus KPV. The K in the name is the extra component. Everything else about the two is the same, including the fact that each compound in the vial has been studied on its own and never as part of this mixture.
Reading a blend label
A blend name is a shortcut, and shortcuts can hide things. A good label and listing should tell you three things without making you guess: every compound in the vial by its full name, the lot number that ties the vial to its certificate, and the house code, which for us is PTY-GLW or PTY-KLW. If a listing gives you only a catchy name and no component list, you cannot check it against the literature, because the literature is written compound by compound. The name on its own tells you nothing about the evidence.
The three shared components
GHK-Cu
GHK-Cu is the copper(II) complex of a three-amino-acid peptide, glycyl-histidyl-lysine, that was first reported in human serum in 1973 (Pickart and Thaler, 1973). It is studied in animal skin-wound models, in cell work on collagen and extracellular matrix synthesis, in cosmetic skin research and in gene-expression profiling (Pickart and Margolina, 2018). The evidence is mostly laboratory and animal work, many of the reviews come from the discoverer's group, and FDA notes limited data in humans.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide described from a protein in gastric juice. Its research covers tendon, ligament and muscle injury models, bone healing in animals, gut mucosal protection models and angiogenesis signaling, with most of the preclinical papers coming from one group in Zagreb (McGuire et al., 2025). Human data are three small pilot reports and no large controlled trials. WADA lists it under S0.
TB-500
TB-500 is a trade name for an N-acetylated seven-residue fragment of thymosin beta-4, residues 17 to 23, identified by analytical chemists in 2012 (Esposito et al., 2012). The fragment is the parent protein's central actin-binding site. Fragment-specific research is mostly anti-doping analytics plus cell migration assays, and whether the fragment reproduces the parent protein's laboratory effects is not established. WADA prohibits thymosin beta-4 and its derivatives under S2.
The fourth component in KLOW: KPV
KPV is the tripeptide lysine-proline-valine. It is the last three residues, positions 11 to 13, of alpha-melanocyte-stimulating hormone, and it has been studied mainly as an anti-inflammatory peptide (Luger and Brzoska, 2007).
Its research areas are mouse colitis models, inflammatory signaling in intestinal cells, oral nanoparticle delivery research and the wider family of melanocortin-derived anti-inflammatory peptides. Cell studies report that KPV is taken up by the PepT1 peptide transporter and is associated with reduced NF-kB and MAP-kinase inflammatory signaling (Dalmasso et al., 2008). Mouse colitis data suggest its effects are at least partly independent of the melanocortin-1 receptor (Kannengiesser et al., 2008), and a 2017 study packaged it in nanoparticles for oral delivery in a mouse model (Xiao et al., 2017).
The mechanism is not well established. No human trials were found on ClinicalTrials.gov, and FDA's compounding review states it identified no human exposure data. KPV is the component with the least human information of the four.
Why there is no combined research
Look at where the four literatures come from. GHK-Cu papers sit in dermatology and matrix biology. BPC-157 papers sit in orthopaedic and gastrointestinal animal research. TB-500 papers sit mostly in anti-doping chemistry. KPV papers sit in gut inflammation. These are different fields, different journals and different labs. None of them has run an experiment on the three- or four-compound mixture, and we did not find one in our research review.
That has a direct consequence for how we write about the blends. We can tell you what each component has been studied for. We cannot tell you what the mixture does, because nobody has measured it. Anyone who tells you otherwise is adding the components' separate findings together, and biology does not add up that neatly.
GLOW vs KLOW side by side
| Item | PTY-GLW blend (GLOW) | PTY-KLW blend (KLOW) |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| Number of compounds | 3 | 4 |
| Added component | None | KPV (alpha-MSH 11-13) |
| Research on the mixture | None published | None published |
| Research stage of components | Preclinical | Preclinical |
| WADA-listed components | BPC-157 (S0), TB-500 (S2) | BPC-157 (S0), TB-500 (S2) |
| Format | Lyophilised powder, one vial | Lyophilised powder, one vial |
How a blend lot is characterised
A certificate for a single compound confirms one identity and one purity. A blend certificate has more to do.
- One identity check per component. Mass spectrometry (MS) should show the expected mass for each peptide in the vial: three for PTY-GLW, four for PTY-KLW. GHK-Cu, KPV, the TB-500 fragment and BPC-157 differ enough in size that each can be picked out.
- Three or four main HPLC peaks. High-performance liquid chromatography separates the components and any impurities. The certificate identifies each principal peak and states the lot's measured purity.
- Content per component. The certificate states how much of each compound the vial holds for that lot.
- Lot number and test date. The lot number should match the one on the vial.
We do not quote a single purity figure across lots. Each lot's certificate states its own measured purity and identity.
Storage
Both blends are supplied as freeze-dried powder. Keep sealed vials cool, dry and out of direct light, and let a cold vial warm to room temperature before opening. These are storage notes for the laboratory, not instructions for use.
Frequently asked questions
What is the difference between KLOW and GLOW?
One compound. GLOW (our PTY-GLW blend) contains GHK-Cu, BPC-157 and TB-500. KLOW (our PTY-KLW blend) contains the same three plus KPV.
Is KLOW a single peptide?
No. KLOW is a blend of four separate peptides in one vial. Each has its own research literature, and none has been studied as part of this mixture.
Has either blend been studied as a combination?
No. Our research review found published work on each component separately and none on the three- or four-compound mixture. That is why this guide summarises the components rather than the blend.
Can I get the components as single vials?
Yes. GHK-Cu, BPC-157, TB-500 and KPV are each listed on their own, which lets a laboratory work with one compound at a time.
See it in the catalogue: PTY-KLW blend and PTY-GLW blend.
For laboratory research use only. Products sold by Amino Party Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.